외벽 경사도에 따른 건물에너지 성능 분석

황우진(Hwang Woo-Jin),신재규(Shin Jae-Kyu),최원기(Choi Won-Ki) 대한건축학회 2011 대한건축학회 학술발표대회 논문집 - 계획계/구조계 Vol.31 No.2(계획계)

This study was performed to analyze the influence of solar transmittance of windows according to incident angle on building energy. The results of this study are follows; 1) Inside sloping window demands lower energy during the cooling season. Conversely, outside sloping window demands lower energy during the heating season. 2) Heating energy is fluctuated within the range of -8∼23 % on slope angle during the heating season, and cooling energy is fluctuated within the rage of -6∼16 % on slop angle during the cooling season. 3) The south zone is first and west, east and north in the order of zone transmitted solar. 4) The annual secondary energy is minimum when the angel of wall slope is 10 degree.

CJ-50001 (recombinant human granulocyte-colony stimulating factor) 의 흰주와 개에서의 약물동태학적 연구

김성남(Sung Nam Kim),신재규(Jae Kyu Shin),이수정(Soo Jung Lee),정용환(Yong Hwan Jung),하석훈(Suk Hoon Ha),김기완(Ki Wan Kim),고형곤(Hyung Kon Koh),김제학(Je Hak Kim) 한국응용약물학회 1998 Biomolecules & Therapeutics(구 응용약물학회지) Vol.6 No.4

The pharmacokinetics of CJ-50001 (recombinant human granulocyte-colony stimulating factor, developed by R&D center of Cheil Jedang Corp.) were investigated in rats and dogs. The serum concentrations of CJ-50001 were measured by a sandwich enzyme immunoassay. After single intravenous (iv) administration of CJ-50001 to rats at a dose of 5 ㎍/kg, the mean terminal half-life and area under the concentration-time curve (AUC) were 0.96 h and 124.49 ㎍·/ml, respectively. After single subcutaneous (sc) administration at the same dose, maximum serum concentration was observed at about 2 hours after administration, and the mean terminal half-life, AUC and the bioavailability were 1.11 h, 63.58 ㎍·h/ml and 51.07%, respectively. In repeated dosing studies, CJ-50001 was administered iv and sc to rats at a daily dose of 5 ㎍/kg for 7 days. The pharmacokinetic parameters, such as mean AUC and terminal half-life, were not significantly different from those of single administration. Following single iv and sc administration of CJ50001 to dogs at a dose of 5 ㎍/kg, mean AUCs were much higher than those of rats, due to the decreased clearence (CL). After sc administration to dogs, maximum serum concentration was observed at 2∼4 hours after administration and the bioavailability was 54.60%.

안지오텐신 2 수용체 길항약 CJ-10513 이 고빈도 심실 pacing 견에서의 혈행동태에 미치는 영향

김영훈(Young Hoon Kim),정성목(Seong Mok Jeong),신재규(Jae Kyu Shin),최재묵(Jae Mook Choi),정성학(Seong Hak Jeong),배훈(Hoon Bae),이건호(Gun Ho Lee),김제학(Je Hak Kim),안양수(Yang Soo An) 한국응용약물학회 1998 Biomolecules & Therapeutics(구 응용약물학회지) Vol.6 No.2

Acute hemodynamic effects of CJ-10513, a non-peptide angiotensin II receptor antagonist, were examined in mongrel dogs treated with high frequency ventricular pacing for one week. Rapid ventricular pacing reduced mean blood pressure (mBP), LVdP/dt and cardiac output (CO), and increased the left ventricular end-diastolic pressure (LVEDP) and pulmonary capillary wedge pressure (PCWP). Continuous infusion of CJ-10513 at doses of 10 and 20 ㎍/kg/min, respectively, for 30 minutes reduced mBP, LVEDP and myocardial oxygen consumption rate (MVO₂) and shifted the cardiac function curve (CO-LVEDP curve) to the left in this dog model. In conclusion, CJ-10513 decreased the preload and afterload and increased the cardiac function in dogs with pacing-induced heart failure.

CJ-50001 (rG-CSF) 의 일반약리작용

김제학(Je Hak Kim),김현수(Hyun Su Kim),김영훈(Young Hoon Kim),정성목(Seong Mok Jeong),신재규(Jae Kyu Shin),최재묵(Jae Mook Choi),고형곤(Hyung Kon Ko) 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.3

CJ-50001 is a recombinant granulocyte-colony stimulating factor (rG-CSF) synthesized by recombinant DNA technology using E. coli as an expression system. The general pharmacological properties of CJ50001 were evaluated in mice, rats, dogs and isolated guinea pig ileum. The doses are 100, 300 and 1,000 ㎍/㎏, i.v. for mice and rats, 1, 10 and 100 ㎍/㎏, i.v. for dogs and 1 and 10㎍/ml for isolated guinea pig ileum. Intravenous administration of CJ-50001 at this dose range did not affect general behavior, central nervous system, smooth muscles, gastrointestinal system, cardiovascular and respiratory system and water and electrolytes excretion. In summary, CJ-50001 had no harmful pharmacological effect in these studies even up to the 200-fold expected clinical dose, 250 ㎍/man.

Vibrio vulnipcus 에 대한 경구용백신 CJ-50002 의 일반약리작용

박완제(Wan Je Park),김영훈(Young Hoon Kim),정성목(Seong Mok Jeong),이영수(Young Soo Lee),신재규(Jae Kyu Shin),최재묵(Jae Mook Choi),이나경(Na Gyong Lee),이윤하(Youn Ha Lee) 한국응용약물학회 1999 Biomolecules & Therapeutics(구 응용약물학회지) Vol.7 No.1

CJ-50002 is an oral vaccine against V. vulnificus infection composed of whole cell lysate of V. vulnificus. The general pharmacological properties of CJ-50002 were evaluated in various animals and in vitro system. CJ-50002 at oral doses of 0.2, 2 and 20 mg/kg had no effect on general behavior in mice, chemoand electro-convulsions in mice, writhing syndrome induced by acetic acid in mice, body temperature in rats, charcoal meal propulsion in mice and urine and electrolytes excretion in rats. However, oral administration of CJ-50002 at dose of 20 mg/kg prolonged the hexobarbital-inuced sleeping inducing time in mice. In anesthetized dogs, CJ-50002 showed no effect on blood pressure, heart rate and ECG but decreased the respiratory rate and femoral blood flow at dose of 20 mg/kg. p.o. CJ-50002 had no effect on the contractile response of the isolated guinea pig ileum to various spasmogen at concentrations of 0.2, 2 and 20 ㎍/ml, respectively. Since these pharmacological effects of CJ-50002 were observed at dose much greater than those in clinical use (approximately 0.16 mg/kg, p.o.), it is likely that this vaccine may be relatively free of undesirable effects in clinical practice.

급·만성 간질환 환자에서 혈청 25-하이드록시 비타민 D_3 농도의 변화에 대한 연구

신재규,한희정,주원찬,송민호,이헌영,노흥규 충남대학교 의과대학 지역사회의학연구소 1998 충남의대잡지 Vol.25 No.1

The liver plays a central role in the vitamin D metabolism; it determines the overall efficiency of vitamin D₃utilization through the 25-hydroxylation of vitamin D. The abnormalities of vitamin D metabolism in acute and chronic liver diseases result from multiple causes such as defects in synthesis of vitamin D binding protein and decreased metabolic activities in 25-hydroxylation of vitamin D. Presumably the severity of liver disease may be related to the low level of vitamin D₃,especially 25-hydroxylated vitamin D₃. We measured the serum 25-hydroxyvitamin D₃in the patients with acute and chronic liver diseases and analyzed their levels according to the severity of liver disease. The patients with acute hepatitis(n=9, M/F;7/2, age 32.3±16.2) and with liver cirrhosis (n=30, M/F;22/8, 55.8±10.5) were subjected to measure serum concentrations of 25-hydroxylated or 1,25-dihydroxylated forms of vitamin D3. Simultaneously we measured serum albumin, serum calcium, parathyroid hormone (PTH) to assess calcium metabolism and the severity of liver disease in those patients. 1) The level of serum 25-hydroxyvitamin D, concentrations in the patients with liver disease (acute hepatitis 12.4±6.4 ng/ml and liver cirrhosis 8.5±4.7 ng/ml, p<0.05) showed significant lower levels compared to normal controls (21.6±9.3 ng/ml) but there was no significant differences in the groups between acute hepatitis and liver cirrhosis. 2) The serum calcium concentrations were not significantly changed in the patients with acute hepatitis (9.06±0.33 mg/dl, p>0.05) but in the patients with liver cirrhosis showed significant decrease in serum calcium levels (8.22±0.57 mg/dl, p<0.05) than those of normal controls (8.76±0.5 mg/dl). 3) The level of serum 1,25-dihydroxyvitamin D₃ concentrations in the patients with liver, cirrhosis showed significant decrease (12.1±10.3 pg/ml, p<0.05) than those of normal controls (35.1±16.2 pg/ml). 4) We could observe the significant positive correlations between serum 25hydroxyvitamin D₃concentrations and serum albumin concentrations in both groups of acute hepatitis (r=0.757, p<0.05, n=9) and liver cirrhosis (r=0.431, p<0.05, n=30). We could observe low serum 25-hydroxyvitamin D, concentrations in patients with acute and chronic liver diseases. This finding suggest that the 25-hydroxylation of vitamin D showed a defect in the early course of liver disease and this is progressively deranged during the course of chronic liver disease. This finding support the causal relationship between liver disease and its metatolic derangement.

폐경후 여성에서 치료 약제에 따른 부위별 골밀도의 변화

안봉수,신재규,주원찬,송민호,노흥규 충남대학교 의과대학 지역사회의학연구소 1996 충남의대잡지 Vol.23 No.2

Because of the prolongation of life span, the postmenopausal osteoporosis is a serious health problem, which needs active preventive and conservative measures. Recent evidence suggests that estrogen replacement therapy .(ERT), calcitonin, bisphosphonate and ipriflavone treatments are effective in preventing bone loss in postmenopausal women. In this study, we evaluated the effects of estrogen, ipriflavone, and combined therapy with estrogen and ipriflavone to BMD in various bone sites (lumbar spine, femoral neck and Ward's triangle). Forty-eight patients were devided into 3 groups by treatment modalities which are estrogen and ipriflavone group (n=12). After basal bone mineral desity (BMD) were determined by DEXA. (Dual energy X-ray absorptiometry. Lunar Radiation Corp. U. S. A. ), the patient were received medication according to each treatment protocol. The patients with estrogen treatment group were 2mg estradiol and 10mg of medroxy progesterone for 21 days a month. The patients of ipriflavone treatment group were received 600mg daily. The patients with combined therapy with estrogen and ipriflavone were received same dose of other two treatment groups. The BMD after treatment were compaired with basal BMD. The results were as follows. 1) The BMD in lumbar spine and femoral neck were significantly increased after estrogen treatment. 2) The BMD in lumar spine was significantly increased after ipriflavone treatment but the BMD in femoral neck and Ward's triangle were not increased with ipriflavone treatment. 3) After combined therapy with estrogen and ipriflavone, the BMD in each sites were increased and the BMD in Ward's triangle was more incresed than estrogen or ipriflavone treatment alone. In conclusion, estrogen prevented cortical bone and trabecular bone loss. ipriflavone prevented trabecular bone loss. The combination with estrogen and ipriflavone was increased effects of estrogen to prevent trabecular bone loss.

그레이브스병 환자에서 방사성 옥소(^131Ⅰ)치료의 효과

노흥규,안봉수,신재규,주언찬,송민호 충남대학교 의과대학 지역사회의학연구소 1996 충남의대잡지 Vol.23 No.2

Graves' disease is characterized by diffuse hyperplasia of thyroid gland, hypersecretion of thyroid hormones, ophthalmopathy, and localized pretibial myxema. Although the pathogenesis of Graves' disease is still obscure, but the TSH receptor antibodies have pathophysiological role in the hyperplasia of the gland and autonomous over production of thyroid hormones through the stimulation of TSH receptor. Radioiodine (^1311I) has been used for the treatment of Graves' disease for many years and is regarded as an treatment for the cases who is not remit following a course of antithyroid drug. To evaluate the efficacy and side effects of radioiodine treatment in Graves' disease, we studied clincal outcome after fixed dose(5-20mCi) of ^131I The results were as followings; 1) The mean dose of 9. 1mCi of ^131I administration makes 12 patients euthyroid out of 41 patients with Graves' disease. The dose of radioiodine(^131I) used for the treatment was not significantly different in hypothyroid group (3/41; 7.3%) or hyperthyroid group(26/41; 63.4%) after ^131I treatment. 2) The clinical outcomes after radioiodine (131I) treatment was not depend on the age and sex and thyrotropin receptor binding inhibitory immunoglobulins(TBII) of radioiodine(^131I) administered patients, but only the short duration of antithyroid drug treatment(the period of observation of the responce to antithyroid drug) before the radioiodine administration increase the incidence of radioiodine induced hypothyroidism. 3) The cumulative incidence of hypothyoidism after radioiodine(^131I) administration was 39.4% after third treatment. In conlusion, radioiodine treatment in fixed-dose is effective; it can induce euthyroidism or hypothyroidism in 33 out of 41 patients without major complications. With this study, we could confirm the efficacy of radioiodine treatment in a minor groups of patient who its difficult to maintain remission after antithyroid drug.

비외상성 척추 압박골절환자에서 척추 골밀도의 변화

주원찬,신재규,한희정,송민호,노흥규 충남대학교 의과대학 지역사회의학연구소 1997 충남의대잡지 Vol.24 No.2

The measurement of bone mineral density(BMD) is important for diagnosis of osteoporosis and prediction of fracture risk in postmenopausal women. We measured bone mineral density in patients with osteoporotic spinal compression fracture group and control group. Here we described clinical changes of bone mineral densities and fracture threshold in postmenopausal women who had the nontraumatic spinal compression fracture. The measurement of BMD were performed by dual energy X-ray absortiometry in 36 postmenopausal patients who had the spinal compression fracture which were evident in simple spine X-ray. The control group (fourteen postmenopausal women) had no back pain and no evident in simple spine X-ray. The mean bone mineral densities from L2-L4 in the pateinets with spinal fracture (0.630±0.114g/㎠) were significantly lower than the control group (0.969±0.156 g/㎠) (p<0.0001). The bone mineral densities were positively correlated with age (n=36, r=36, p<0.05). The number of spine fracture were increased with in patents who showed low bone mineral densities, high T score, low body mass index and early menopause. The most frequent site of compression fracture were noted at L1, T12, L2 and L4, L3, The fracture threshold definded by Riggs was 0.793 g/㎠ in theses patients. In conclusion, the patients with nontraumatic spinal compression fracture showed signifcantly low bone mineral densitie and T score and the fracture threshold was 0.793 g/㎠.

갑상선 악성결절에 대한 미세침흡인검사와 침생검의 진단적 의의

노흥규,신재규,주원찬,한희정,송민호 충남대학교 의과대학 지역사회의학연구소 1997 충남의대잡지 Vol.24 No.2

To evaluate the usefulness. of fine needle aspiration (FNA) cytology and biopsy for the detection of malignant thyroid nodules in nodular nontoxic goiter. We retropsectively analyzed 70 patients who had the nodular nontoxic goiter which is highly suspicious by the cytological and biopsy findings. The results were as follows: 1) Out of 70 patients who were thyroidectomized for malignant nodules, 63 (88.6%) patients were women and 7 (11.4%) men. 2) Sensitivity and specificity of FNA cytology for the detection of malignant thyroid nodule were 72% and 15.4% respectively. 3) Sensitivity and specificity of biopsy for the detection of malignant thyroid nodule were 97.4% and 33.3%, respectively. 4) Sensitivity and specificity of combination of FNA cytology and biopsy for detection of malignant thyroid nodule were 95% and 100%m respectively. 5) Malignant thyroid nodules were almost (93.4%) cold nodules in ^99m-Tc thyroid scan single nodule (72.7%) was more common than multiple nodules, location of lesion was 1.99 times more common in right lobe than in left lobe in malignant thyroid nodule. 6) Regional lymph node and distant metastasis were identified in 43%, 3.7% of malignant thyroid nodules, respectively. We concluded that preoperative biopsy may increased detection rate of malignant thyroid nodule with benign findings in FAN cytology.